617703-01-2

Basic information

• Product Name: N-(2-(tert-butoxycarbonylamino)phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
• Synonyms: N-(2-(tert-butoxycarbonylamino)phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
• CAS NO: 617703-01-2
• Molecular Weight: 438.332
• Mol File: 617703-01-2.mol

Chemical Properties

• CAS DataBase Reference: N-(2-(tert-butoxycarbonylamino)phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-(tert-butoxycarbonylamino)phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide(617703-01-2)
• EPA Substance Registry System: N-(2-(tert-butoxycarbonylamino)phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide(617703-01-2)

Safety Data

• Hazardous Substances Data: 617703-01-2(Hazardous Substances Data)

Upstream product

• 617703-02-3 N-(2-t-butoxycarbonylaminophenyl)-4-bromobenzamide 
• 73183-34-3 bis(pinacol)diborane 
• 146651-75-4 tert–butyl (2–aminophenyl)carbamate 
• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 

Downstream Products

• 1030927-09-3 N-(2-(tert-butoxycarbonylamino)phenyl)-4-(3-cyano-5-formylpyridin-2-yl)benzamide 
• 1384485-42-0 tert-butyl [2-({4-[3-cyano-5-(morpholin-4-ylmethyl)pyridin-2-yl]benzoyl}amino)phenyl]carbamate 
• 1026474-40-7 N-(2-aminophenyl)-4-[3-cyano-5-[(4-isopropylpiperazin-1-yl)methyl]-2-pyridyl]benzamide 
• 1384485-43-1 tert-butyl [2-({4-[5-(chloromethyl)-3-cyanopyridin-2-yl]benzoyl}amino)phenyl]carbamate 
• 1384485-38-4 C₂₄H₂₃N₅O₂ 
• 901300-01-4 N-(2-aminophenyl)-4-(3-methylpyridin-2-yl)benzamide 
• 901300-50-3 tert-butyl (2-{[4-(3-methyl-5-nitropyridin-2-yl)benzoyl]amino}phenyl)carbamate 
• 901300-13-8 6-{4-[({2-[(tert-butoxycarbonyl)amino]phenyl}amino)carbonyl]phenyl}-5-methylnicotinic acid 
• 901300-03-6 tert-butyl (2-{[4-(5-formyl-3-methylpyridin-2-yl)benzoyl]amino}phenyl)carbamate 
• 934828-17-8 benzyl 4-{4-[({2-[(tert-butoxycarbonyl)amino]phenyl}amino)carbonyl]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate 
• 900176-67-2 tert-butyl [2-({4-[3-chloro-5-(hydroxymethyl)pyridin-2-yl]benzoyl}amino)phenyl]carbamate 
• 900176-59-2 tert-butyl (2-{[4-(3-chloropyridin-2-yl)benzoyl]amino}phenyl)carbamate 
• 900176-97-8 6-{4-[({2-[(tert-butoxycarbonyl)amino]phenyl}amino)carbonyl]phenyl}-2-chloro-5-fluoronicotinic acid 
• 891863-20-0 tert-butyl (2-{[4-(5-formyl-1,3-thiazol-2-yl)benzoyl]amino}phenyl)carbamate 

Relevant articles and documents

Flexible and scalable route to HDAc inhibitors containing an unusual trisubstituted pyridine core

A scalable route to histone deacetylase inhibitors containing an unusual 2-aryl-3-cyano-5-aminomethylpyridine core has been developed which has the flexibility to deliver a range of compounds on at least a multigram scale. The key step involves a novel Ma

Benzamide Compounds

The invention concerns benzamide compounds of Formula (I), wherein R1a, R1b, R1c, R2, R3, R4, m and n have any of the meanings defined in the description; processes for their preparation, p

Design and campaign synthesis of pyridine-based histone deacetylase inhibitors

A lead benzamide, bearing a cyanopyridyl moiety (3), was identified as a potent and low molecular weight histone deacetylase (HDAC) inhibitor. Various replacements of the cyano group were explored at the C3-position, along with the exploration of solubility-enhancing groups at the C5-position. It was determined that cyano substitution at the C3-position of the pyridyl core, along with a methylazetidinyl substituent at the C5-position yielded optimal HDAC1 inhibition and anti-proliferative activity in HCT-116 cells.

BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS

The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluromethyl and cyano; p is 0-4; and R3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by histone deacetylase